{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:03:41Z","timestamp":1784120621453,"version":"3.55.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between glucagon-like peptide-1 (GLP-1) based therapy and small-bowel transit time during capsule endoscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, multicentre, observational study of consecutive adults undergoing small-bowel capsule endoscopy for standard clinical indications. Patients receiving GLP-1-based therapy, defined as treatment with a GLP-1 receptor agonist or dual glucose-dependent insulinotropic polypeptide\/GLP-1 receptor agonist, were compared with non-exposed controls. The primary outcome was small-bowel transit time. Secondary outcomes included gastric transit time, capsule completion, bowel preparation quality, repeat-examination recommendation and endoscopic findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 129 participants, 34 were receiving GLP-1-based therapy and 95 were non-exposed controls. Exposed patients had longer unadjusted small-bowel transit time than controls (median 311.0 (IQR 252.8\u2013433.0)\u2009vs 236.0 (188.0\u2013282.5)\u2009min; p&lt;0.001). Gastric transit time was not significantly different between groups (33.5 (15.2\u201351.8)\u2009vs 22.5 (11.0\u201342.5)\u2009min; p=0.263). Capsule completion was numerically lower among exposed patients, but the difference was not statistically significant (91.2% vs 98.9%; p=0.056). Repeat capsule recommendation (11.8% vs 3.2%; p=0.078) and clinically significant endoscopic findings (23.5% vs 34.7%; p=0.322) were also not significantly different. In multivariable linear regression restricted to examinations with calculable small-bowel transit time and complete covariate data, GLP-1-based therapy was independently associated with longer small-bowel transit time after adjustment for age, body mass index, diabetes mellitus and indication for capsule endoscopy (adjusted \u03b2+83\u2009min, 95% CI 3.1 to 162.8; p=0.042).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1-based therapy was associated with longer small-bowel transit time during capsule endoscopy. These findings do not support routine discontinuation of GLP-1-based therapy before capsule endoscopy, but they support individualised assessment and larger studies powered to evaluate capsule completion and repeat examination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2026-002360","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:05:20Z","timestamp":1784117120000},"page":"e002360","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-7180","authenticated-orcid":false,"given":"Fadi Abu","family":"Baker","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel"},{"name":"Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Melhem","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Assuta Medical Center, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Kalnizki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Assuta Medical Center, Ra'anana, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Khader","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Assuta Medical Center, Beer-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Dardik","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9865-0785","authenticated-orcid":false,"given":"Mifleh","family":"Tatour","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-118X","authenticated-orcid":false,"given":"Rawi","family":"Hazzan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Assuta Medical Center, Haifa, Israel"},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071505050992000_13.1.e002360.1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026071505050992000_13.1.e002360.2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27 Suppl 2","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026071505050992000_13.1.e002360.3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.gie.2024.10.057","article-title":"American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors","volume":"101","author":"Sharaiha","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"2026071505050992000_13.1.e002360.4","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"2026071505050992000_13.1.e002360.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01079.x"},{"key":"2026071505050992000_13.1.e002360.6","doi-asserted-by":"crossref","first-page":"102012","DOI":"10.1016\/j.bpg.2025.102012","article-title":"How to measure quality in capsule endoscopy","volume":"76","author":"Salvi","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026071505050992000_13.1.e002360.7","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496"},{"key":"2026071505050992000_13.1.e002360.8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026071505050992000_13.1.e002360.9","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0158"},{"key":"2026071505050992000_13.1.e002360.10","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001789","article-title":"Impact of GLP-1 receptor agonists on whole-gut gastrointestinal motility using wireless motility capsule: a descriptive single-center case series","volume":"12","author":"Cymbal","year":"2025","journal-title":"ACG Case Rep J"},{"key":"2026071505050992000_13.1.e002360.11","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.14309\/ajg.0000000000003362","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy: a systematic review and meta-analysis","volume":"120","author":"Beran","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026071505050992000_13.1.e002360.12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/a-2419-3875","article-title":"Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy","volume":"57","author":"Abu-Freha","year":"2025","journal-title":"Endoscopy"},{"key":"2026071505050992000_13.1.e002360.13","doi-asserted-by":"crossref","unstructured":"Jalleh RJ , Plummer MP , Marathe CS , et al . Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab 2024;1\u201315. doi:10.1210\/clinem\/dgaf387","DOI":"10.1210\/clinem\/dgae719"},{"key":"2026071505050992000_13.1.e002360.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14155597","article-title":"GLP-1 receptor agonists and gastrointestinal endoscopy: a narrative review of risks, management strategies, and the need for clinical consensus","volume":"14","author":"Crespo","year":"2025","journal-title":"J Clin Med"},{"key":"2026071505050992000_13.1.e002360.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-025-00995-3","article-title":"Gastrointestinal motility effects of GLP-1 receptor agonists","volume":"27","author":"Bellavance","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"2026071505050992000_13.1.e002360.16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"key":"2026071505050992000_13.1.e002360.17","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13102362","article-title":"Gastrointestinal symptoms in obesity therapy: mechanisms, epidemiology, and management strategies","volume":"13","author":"Witaszek","year":"2025","journal-title":"Biomedicines"},{"key":"2026071505050992000_13.1.e002360.18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026071505050992000_13.1.e002360.19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.gie.2024.07.014","article-title":"Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study","volume":"101","author":"Odah","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"2026071505050992000_13.1.e002360.20","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.3390\/jcm13185627","article-title":"Impact of GLP-1 receptor agonists in gastrointestinal endoscopy: an updated review","volume":"13","author":"Singh","year":"2024","journal-title":"JCM"},{"key":"2026071505050992000_13.1.e002360.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071505050992000_13.1.e002360.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.002"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:05:26Z","timestamp":1784117126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjgast-2026-002360"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002360","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}